RESEARCH STUDIES BPC-157 Research Applications & Published Studies BPC-157 research spans more than two decades of published preclinical literature
A 2025 safety study confirmed IV BPC-157 was well tolerated in healthy adults with no adverse events
In the comprehensive preclinical studies, MDR-001 has demonstrated excellent functional potency and selectivity, with favorable ADME properties and oral bioavailability, as well as desirable pharmacokinetics and tolerability
Remarkably none of these drugs obtained approval for use in cancer treatment
Medication waste also occurs when patients do not properly store tirzepatide or lose track of expiration dates
For functional enrichment analysis, the R package gprofiler2 (v.0.2.0) was used to identify enriched functional terms (GO:MF, GO:BP, GO:CC, KEGG pathways and REACTOME pathways)